ClinicalTrials.gg

Program

KAT6 Inhibitor MEN2312

Its studies are mostly in Breast Neoplasms · Hematologic Neoplasms, led by Menarini Group.

Furthest: phase 2, since Oct 8, 20262 company-led studies, 2 open or runningNext primary completion: Oct 24, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Menarini Group22 open or runningphase 2since Oct 8, 2026Oct 9, 2024Oct 24, 2027phase 1 · NCT06638307

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 9, 2024First study: phase 1 study in Advanced Breast CancerFirst studyNCT06638307 · 240 planned · United States, Spain
  2. Oct 8, 2026Phase 2 study in Hematologic NeoplasmsPhase 2 reachedNCT07873827 · 115 planned

Ahead

  1. Oct 24, 2027Primary completion: phase 1 study in Advanced Breast CancerNCT06638307
  2. May 12, 2028Primary completion: phase 2 study in Hematologic NeoplasmsNCT07873827

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07873827Hematologic Neoplasms2Not yet recruitingMay 12, 2028115
NCT06638307Advanced Breast Cancer · United States, Spain1RecruitingOct 24, 2027240

How it is read

Names in the registry

  • “MEN2312”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.